These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29997152)

  • 1. Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer.
    Hsu HC; Lapke N; Wang CW; Lin PY; You JF; Yeh CY; Tsai WS; Hung HY; Chiang SF; Chen HC; Chen SJ; Hsu A; Yang TS
    Mol Cancer Ther; 2018 Oct; 17(10):2238-2247. PubMed ID: 29997152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer.
    Jia N; Chang L; Gao X; Shi X; Dou X; Guan M; Shao Y; Li N; Cheng Y; Ying H; Sun Z; Zhou Y; Zhao L; Zhou J; Bai C
    BMC Cancer; 2021 Jul; 21(1):845. PubMed ID: 34294055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
    Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
    Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
    Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
    Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
    Sci Rep; 2019 Nov; 9(1):17358. PubMed ID: 31758080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
    Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.
    Max Ma X; Bendell JC; Hurwitz HI; Ju C; Lee JJ; Lovejoy A; Mancao C; Nicholas A; Price R; Sommer N; Tikoo N; Yao L; Yaung SJ; Palma JF
    Clin Cancer Res; 2020 Aug; 26(15):4010-4017. PubMed ID: 32220893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
    Tie J; Kinde I; Wang Y; Wong HL; Roebert J; Christie M; Tacey M; Wong R; Singh M; Karapetis CS; Desai J; Tran B; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2015 Aug; 26(8):1715-22. PubMed ID: 25851626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
    Manca P; Corallo S; Busico A; Lonardi S; Corti F; Antoniotti C; Procaccio L; Clavarezza M; Smiroldo V; Tomasello G; Murialdo R; Sartore-Bianchi A; Racca P; Pagani F; Randon G; Martinetti A; Sottotetti E; Palermo F; Perrone F; Tamborini E; Prisciandaro M; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F
    Clin Cancer Res; 2021 May; 27(9):2505-2514. PubMed ID: 33547199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.
    Lim Y; Kim S; Kang JK; Kim HP; Jang H; Han H; Kim H; Kim MJ; Lee KH; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Sci Rep; 2021 Aug; 11(1):16333. PubMed ID: 34381078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.
    Thomsen CB; Hansen TF; Andersen RF; Lindebjerg J; Jensen LH; Jakobsen A
    J Exp Clin Cancer Res; 2018 Mar; 37(1):55. PubMed ID: 29530101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
    Lyskjær I; Kronborg CS; Rasmussen MH; Sørensen BS; Demuth C; Rosenkilde M; Johansen AFB; Knudsen M; Vang S; Krag SRP; Spindler KG; Andersen CL
    Sci Rep; 2019 Aug; 9(1):11542. PubMed ID: 31395942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.
    Schøler LV; Reinert T; Ørntoft MW; Kassentoft CG; Árnadóttir SS; Vang S; Nordentoft I; Knudsen M; Lamy P; Andreasen D; Mortensen FV; Knudsen AR; Stribolt K; Sivesgaard K; Mouritzen P; Nielsen HJ; Laurberg S; Ørntoft TF; Andersen CL
    Clin Cancer Res; 2017 Sep; 23(18):5437-5445. PubMed ID: 28600478
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
    Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
    Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
    Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
    Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
    Nakamura Y; Yoshino T
    Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
    Ikeda S; Lim JS; Kurzrock R
    Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.